Katsuyuki Maki

In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi

Shuichi Tawara, Fumiaki Ikeda, Katsuyuki Maki et al. · Antimicrobial Agents and Chemotherapy · 2000 · 311 citations

Life Sciences, Microbiology, Pharmacology +17

Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis

Fumiaki Ikeda, Yoshimi Wakai, Satoru Matsumoto et al. · Antimicrobial Agents and Chemotherapy · 2000 · 147 citations

Medicine, Infectious Diseases, Pharmacology +17

Overexpression of<i>Candida albicans CDR1</i>,<i>CDR2</i>, or<i>MDR1</i>Does Not Produce Significant Changes in Echinocandin Susceptibility

Kyoko Niimi, Katsuyuki Maki, Fumiaki Ikeda et al. · Antimicrobial Agents and Chemotherapy · 2006 · 137 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity

Kyoko Niimi, Brian C. Monk, Asuka Hirai et al. · Journal of Antimicrobial Chemotherapy · 2010 · 48 citations

Life Sciences, Genetics, Microbiology +17

FR290581, a novel sordarin derivative: Synthesis and antifungal activity

Tadaatsu Hanadate, Masaki Tomishima, Nobuyuki Shiraishi et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 36 citations

Pharmacy, Chemistry, Medicinal Chemistry +10